GO:0035662 Toll-like receptor 4 binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035662 (Toll-like receptor 4 binding) is a molecular function describing the selective physical interaction of a protein with TLR4, the pattern recognition receptor for bacterial lipopolysaccharide (LPS).
• The best-characterized ligand is MD-2 (LY96), which binds the TLR4 ectodomain and directly contacts LPS, forming the activated TLR4-MD-2-LPS complex.
• Small molecules such as TAK-242 (resatorvid) bind TLR4 selectively and block its interaction with adaptor proteins, proving that TLR4 binding is a druggable interface.
• TLR4-binding proteins participate in infection, thrombosis, neuroinflammation and inflammatory bowel disease, making this function clinically relevant [2,4,6].
• Evolutionary analysis shows that the TLR4 pathway emerged early and diversified, which explains why TLR4-binding interfaces are conserved yet species-specific.
• CRISPR knockout, point-mutation, knock-in and overexpression models are the standard tools for testing whether a candidate TLR4-binding protein is causally involved in a phenotype [1,8].
Description
Toll-like receptor 4 binding (GO:0035662) is the molecular function of selectively and non-covalently interacting with TLR4, the pattern recognition receptor that recognizes bacterial lipopolysaccharide (LPS) and initiates innate immune signaling. Because TLR4 sits at the first line of host defense, the proteins that bind it act as gatekeepers that determine whether an inflammatory response is launched, tuned or silenced [3,7]. Researchers annotate this function when a protein physically associates with TLR4, as demonstrated for the accessory molecule MD-2, which binds the TLR4 ectodomain and directly contacts LPS. The interaction is not merely structural: the small-molecule inhibitor TAK-242 (resatorvid) binds TLR4 selectively and interferes with the recruitment of TLR4 adaptor molecules, showing that the TLR4-binding interface is functionally decisive and pharmacologically tractable. Consequently, GO:0035662 is a high-value annotation for immunology, infectious disease and inflammation research, and it is increasingly used to interpret CRISPR screens and interactome datasets [1,7].
Toll-like receptor 4 binding At A Glance
| GO ID | GO:0035662 |
|---|---|
| GO term | Toll-like receptor 4 binding |
| Ontology | molecular_function |
| Synonym | TLR4 binding |
| Definition | Binding to a Toll-like 4 protein, a pattern recognition receptor that binds bacterial lipopolysaccharide (LPS) to initiate an innate immune response. |
| Major function | Physical recognition of TLR4, enabling assembly of the LPS-sensing receptor complex and modulation of innate immune signaling. |
| Representative binder | MD-2 (LY96), the TLR4 accessory protein that binds the TLR4 ectodomain and contacts LPS. |
| Pharmacological probe | TAK-242 (resatorvid) binds TLR4 selectively and disrupts TLR4-adaptor interactions. |
| Disease relevance | Implicated in infection-driven thrombosis, Crohn's disease and neuroinflammation [2,4,6]. |
What Is GO:0035662?
In practical terms, GO:0035662 describes the ability of a protein to bind a Toll-like receptor 4 (TLR4) protein. TLR4 is a pattern recognition receptor that binds bacterial lipopolysaccharide (LPS) to initiate an innate immune response. A gene product annotated with this term therefore participates directly in the TLR4 recognition complex or in its regulation through physical contact, rather than merely acting downstream in the signaling cascade.
Why Is Toll-like receptor 4 binding Important in Cell Biology?
GO:0035662 matters because the physical interaction between a protein and TLR4 is the molecular decision point that converts LPS detection into inflammation. Structural work established that MD-2 binds TLR4 and directly engages LPS, defining the minimal recognition unit of the innate immune system. Pharmacological validation showed that occupying the TLR4-binding interface with TAK-242 blocks adaptor recruitment and downstream signaling, confirming that this function can be therapeutically modulated. Clinically, TLR4-binding events have been linked to platelet-related thrombosis in SARS-CoV-2 infection and to inflammatory bowel disease, indicating that this molecular function contributes to both acute and chronic human pathology [2,4]. Because TLR4 signaling is also a central node in neuroinflammation, bioactive-compound and drug-discovery programs routinely target TLR4-binding interfaces [5,6]. Finally, evolutionary studies of the TLR4 pathway show that this binding function emerged early and diversified across species, which is essential context for translating animal-model findings to humans.
• Defines the minimal molecular event required for LPS recognition and innate immune activation.
• Provides a druggable interface validated by the TLR4-selective inhibitor TAK-242.
• Links directly to infection-associated platelet activation and thrombosis in SARS-CoV-2.
• Contributes to chronic intestinal inflammation in Crohn's disease through platelet TLR4.
• Is a target of bioactive compounds that modulate TLR4-mediated inflammation.
• Underpins therapeutic strategies for TLR4-mediated neuroinflammation.
• Shows an evolutionary trajectory that explains functional emergence and species differences.
• Can be triggered or enhanced by host-derived ligands such as extracellular IFI16 in the presence of LPS.
• Serves as an annotation anchor for interpreting CRISPR screens and protein-interaction datasets [1,7].
• Enables mechanistic separation of ligand binding from downstream adaptor signaling [1,3].
What Happens During Toll-like receptor 4 binding?
Ligand recognition and receptor engagement
In simple terms: First, the receptor must grab the bacterial molecule and its binding partner must hold on to the receptor.
TLR4 binding begins with recognition of bacterial lipopolysaccharide (LPS). Structural analysis of the TLR4-MD-2 complex showed that MD-2 binds the TLR4 ectodomain and directly contacts LPS, forming the core recognition unit that positions the ligand for receptor activation. This step is the defining event of GO:0035662 because it is the physical binding of a protein to TLR4 that licenses subsequent signaling.
Complex assembly and adaptor recruitment
In simple terms: Once the receptor is occupied, it must recruit partner proteins inside the cell to transmit the signal.
After ligand engagement, the TLR4 complex must interact with adaptor molecules to propagate the signal. TAK-242 (resatorvid) binds TLR4 selectively and interferes with interactions between TLR4 and its adaptor molecules, demonstrating that the TLR4-binding interface is required for adaptor recruitment and downstream signaling. This makes adaptor coupling a functional readout of TLR4 binding.
Amplification in immune and non-immune cells
In simple terms: The signal is not limited to immune cells; platelets and other cells can use TLR4 binding to amplify inflammation.
TLR4-dependent responses extend beyond classical immune cells. Platelet TLR4 has been implicated in Crohn's disease, showing that TLR4-binding events in platelets contribute to inflammatory pathology. In SARS-CoV-2 infection, TLR4-dependent platelet-related thrombosis has been described, linking TLR4 binding to coagulation and vascular complications.
Host-derived ligand enhancement
In simple terms: Host molecules can also engage this system and make the response stronger when bacterial LPS is present.
Extracellular IFI16 can trigger TLR4-mediated inflammation, and this response is enhanced by lipopolysaccharide binding, indicating that host-derived factors can cooperate with LPS to amplify TLR4-dependent signaling. This broadens the physiological contexts in which TLR4-binding proteins operate beyond direct bacterial recognition.
Key Genes Involved in GO:0035662 Toll-like receptor 4 binding
The following genes and proteins are experimentally linked to TLR4 binding, LPS recognition or TLR4-dependent inflammatory signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TLR4 | Pattern recognition receptor that binds LPS and initiates innate immune signaling | Central receptor for GO:0035662; target of TAK-242 and genetic models [1,3] |
| LY96 (MD-2) | Accessory protein that binds the TLR4 ectodomain and directly contacts LPS | Defines the structural basis of TLR4 binding |
| MYD88 | Adaptor recruited downstream of TLR4 activation | Readout of TLR4-adaptor coupling disrupted by TAK-242 |
| TICAM1 (TRIF) | Alternative adaptor for TLR4 signaling | Used to distinguish MyD88-dependent and independent branches |
| IFI16 | Host factor that triggers TLR4-mediated inflammation enhanced by LPS | Links host-derived ligands to TLR4 binding |
| CD14 | Co-receptor that presents LPS to the TLR4-MD-2 complex | Supports ligand delivery to the TLR4-binding interface |
| LY86 (MD-1) | MD-2-related lipid-recognition protein | Comparative context for TLR4-binding accessory proteins |
| NFKB1 | Transcription factor activated downstream of TLR4 | Functional endpoint of TLR4 binding |
| IL6 | Cytokine induced by TLR4 signaling | Inflammatory readout in TLR4-binding studies |
| TNF | Cytokine induced by TLR4 signaling | Inflammatory readout in TLR4-binding studies |
| NLRP3 | Inflammasome component linked to TLR4-driven inflammation | Context for TLR4-mediated inflammatory pathways |
| P2RY12 | Platelet receptor relevant to thrombosis | Platelet-related thrombosis context for TLR4 |
| ITGA2B | Platelet integrin involved in aggregation | Platelet activation readout in TLR4 studies |
| SELP (P-selectin) | Platelet activation marker | Thrombosis and inflammation readout |
| CASP1 | Inflammatory caspase downstream of inflammasome activation | Links TLR4 binding to inflammatory cell death |
| CXCL8 (IL-8) | Chemokine induced by inflammatory signaling | Neutrophil recruitment readout |
| CCL2 | Chemokine involved in monocyte recruitment | Neuroinflammation and inflammation readout |
| TLR2 | Related TLR family member | Comparative specificity control for TLR4 binding |
How Is Toll-like receptor 4 binding Regulated?
TLR4 binding and its downstream consequences are regulated at multiple levels. Pharmacological regulation is exemplified by TAK-242, which binds TLR4 selectively and interferes with TLR4-adaptor interactions, effectively uncoupling receptor occupancy from signaling. Ligand availability provides another layer: MD-2 binding to TLR4 and direct LPS contact determine whether the receptor complex can assemble. Host-derived ligands such as extracellular IFI16 can trigger TLR4-mediated inflammation, and this response is enhanced by lipopolysaccharide binding, showing that cooperative ligand interactions tune the strength of TLR4-dependent responses. In disease contexts, platelet TLR4 activity is associated with Crohn's disease and with SARS-CoV-2-related thrombosis, indicating that cellular context and platelet activation state influence the functional output of TLR4 binding [2,4]. Bioactive compounds that modulate TLR4-mediated inflammation further demonstrate that this function is responsive to dietary and pharmacological intervention.
Toll-like receptor 4 binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TLR4 | SARS-CoV-2-associated platelet thrombosis | Platelet-specific knockout or point-mutation models |
| TLR4 | Crohn's disease intestinal inflammation | Intestinal epithelial or platelet knockout models |
| LY96 (MD-2) | LPS recognition and innate immune activation | Knock-in of MD-2 binding-interface mutations |
| IFI16 | TLR4-mediated inflammation enhanced by LPS | Overexpression and knockout in macrophage models |
| MYD88 | TLR4 adaptor signaling in inflammation | Knockout and point-mutation models |
TLR4 binding in infection-associated thrombosis
TLR4-dependent platelet-related thrombosis has been described in SARS-CoV-2 infection, linking the molecular function of TLR4 binding to coagulation and vascular pathology. This suggests that proteins annotated with GO:0035662 may contribute to thromboinflammatory complications during viral infection.
TLR4 binding in inflammatory bowel disease
Platelet TLR4 has been studied in Crohn's disease, where TLR4-dependent platelet activity is associated with inflammatory pathology. This connects TLR4 binding to chronic intestinal inflammation and provides a rationale for evaluating TLR4-binding proteins in gut inflammation models.
TLR4 binding in neuroinflammation
Therapeutic developments targeting TLR4-mediated neuroinflammation highlight TLR4 binding as a druggable node in central nervous system inflammation. Compounds and biologics that interfere with TLR4 binding are therefore explored as neuroprotective strategies.
TLR4 binding and host-derived ligands
Extracellular IFI16 triggers TLR4-mediated inflammation that is enhanced by lipopolysaccharide binding, indicating that host-derived molecules can cooperate with bacterial ligands to drive TLR4-dependent disease processes. This expands the disease contexts in which TLR4-binding proteins may be relevant.
From Toll-like receptor 4 binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is TLR4 binding required for LPS-induced signaling? | TLR4 or LY96 knockout cells |
| Does a specific residue mediate TLR4-adaptor coupling? | Point-mutation knock-in of the TLR4 or adaptor interface |
| Can a candidate protein bind TLR4 in living cells? | Tagged knock-in of the candidate gene with a proximity label |
| Does overexpression of a TLR4-binding protein amplify inflammation? | Overexpression cell models with cytokine readouts |
| Which genes modify TLR4-dependent thrombosis? | CRISPR library screening in platelet or macrophage models |
| Is a TLR4-binding interface conserved across species? | Comparative knock-in and evolutionary analysis |
How to Study the Toll-like receptor 4 binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical interaction between a protein and TLR4 | Validation of GO:0035662 annotations |
| Surface plasmon resonance | Binding affinity and kinetics | Small-molecule or protein binding to TLR4 |
| Crystallography | Atomic structure of the TLR4-ligand complex | Defining MD-2 and LPS contacts |
| NF-kB reporter assay | Downstream signaling activation | Functional readout of TLR4 binding |
| Cytokine ELISA | Inflammatory cytokine secretion | TLR4-mediated inflammation studies |
| Platelet aggregation assay | Platelet activation and thrombosis | TLR4-dependent thrombosis models |
| CRISPR knockout screening | Genes required for a TLR4-dependent phenotype | Discovery of novel TLR4-binding modulators |
| Overexpression models | Gain-of-function effects of a candidate binder | Testing host-derived ligand enhancement |
Biochemical binding assays
Direct binding of proteins to TLR4 can be assessed by co-immunoprecipitation, pull-down and surface plasmon resonance, as exemplified by the demonstration that TAK-242 binds TLR4 selectively and disrupts TLR4-adaptor interactions. Structural approaches such as crystallography defined how MD-2 binds TLR4 and contacts LPS.
Cell-based signaling readouts
TLR4 binding is functionally inferred from downstream readouts such as NF-kB activation and cytokine induction. TAK-242 studies used interference with TLR4-adaptor interactions as a functional endpoint, while inflammatory cytokine measurements are standard in TLR4 studies.
Platelet and thrombosis assays
Because TLR4-dependent platelet-related thrombosis occurs in SARS-CoV-2 infection, platelet activation and aggregation assays are used to connect TLR4 binding to thrombotic phenotypes. Platelet TLR4 has also been evaluated in Crohn's disease, linking binding function to clinical samples.
Genetic and CRISPR-based perturbation
Knockout, point-mutation and knock-in models are used to test causality of TLR4-binding proteins. Evolutionary and functional emergence studies provide a framework for interpreting pathway conservation across species, and host-derived ligand studies use overexpression and knockout to dissect TLR4-dependent inflammation.
How CRISPR Can Be Used to Study GO:0035662 Toll-like receptor 4 binding
Knockout
CRISPR knockout of TLR4, LY96 or candidate binding partners is used to test whether the interaction is required for LPS-induced signaling and inflammation. Knockout of TLR4 or its adaptors abolishes downstream readouts, providing a clean negative control for GO:0035662 studies [1,3].
Point Mutation
Point-mutation models can disrupt specific residues at the TLR4-binding interface to separate binding from signaling. This approach is supported by evidence that TAK-242 interferes with TLR4-adaptor interactions, implying that discrete interface residues mediate coupling.
Knock-in
Tagged knock-in of candidate TLR4-binding proteins enables proximity labeling and endogenous interaction mapping. Structural knowledge of the TLR4-MD-2-LPS complex guides the design of knock-in alleles that preserve or disrupt binding.
Overexpression
Overexpression of TLR4-binding proteins or host-derived ligands such as IFI16 is used to test gain-of-function inflammatory phenotypes, especially in the presence of LPS. Overexpression models also help evaluate bioactive compounds that modulate TLR4-mediated inflammation.
How EDITGENE Supports Toll-like receptor 4 binding Research
Researchers studying Toll-like receptor 4 binding-related genes often need to determine whether a candidate gene is causally involved in TLR4-dependent inflammation or merely correlated with it. Establishing causality requires precise genetic perturbation, because TLR4 binding sits at the top of a signaling cascade that can be influenced by many indirect factors [1,3]. EDITGENE provides the full spectrum of CRISPR cell-model services needed to move from annotation to mechanism.
Contact EDITGENE today to design your custom CRISPR model for Toll-like receptor 4 binding research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| S100A9 Knockout A-549 Cell Line | EDC90108 | Human | 6280 | Details Get a Quote |
| TIRAP Knockout HEK293 Cell Line | EDJ-KQ594 | Human | 114609 | Details Get a Quote |
| DAB2IP Knockout HEK293 Cell Line | EDJ-KQ1489 | Human | 153090 | Details Get a Quote |
| S100A8 Knockout HEK293 Cell Line | EDJ-KQ2361 | Human | 6279 | Details Get a Quote |
| LY96 Knockout HEK293 Cell Line | EDJ-KQ3149 | Human | 23643 | Details Get a Quote |
| S100A9 Knockout HEK293 Cell Line | EDJ-KQ5702 | Human | 6280 | Details Get a Quote |
| TIRAP Knockout A-549 Cell Line | EDJ-KQ19032 | Human | 114609 | Details Get a Quote |
| TIRAP Knockout HCT 116 Cell Line | EDJ-KQ19033 | Human | 114609 | Details Get a Quote |
| TIRAP Knockout HeLa Cell Line | EDJ-KQ19034 | Human | 114609 | Details Get a Quote |
| DAB2IP Knockout A-549 Cell Line | EDJ-KQ21081 | Human | 153090 | Details Get a Quote |
| DAB2IP Knockout HCT 116 Cell Line | EDJ-KQ21082 | Human | 153090 | Details Get a Quote |
| DAB2IP Knockout HeLa Cell Line | EDJ-KQ21083 | Human | 153090 | Details Get a Quote |
| S100a8 Knockout RAW 264.7 Cell Line | EDJ-KZ441 | Mouse | 20201 | Details Get a Quote |
| S100A8 Knockout HeLa Cell Line | EDJ-KQ54378 | Human | 6279 | Details Get a Quote |
| S100A9 Knockout HeLa Cell Line | EDJ-KQ54379 | Human | 6280 | Details Get a Quote |
Displaying Records 1 To 15 Of 21 Records
Frequently Asked Questions About Toll-like receptor 4 binding
What is GO:0035662?
GO:0035662 is the Gene Ontology molecular function term for Toll-like receptor 4 binding, defined as binding to a TLR4 protein, the pattern recognition receptor that binds bacterial lipopolysaccharide to initiate innate immunity.
What is Toll-like receptor 4 binding?
It is the physical, non-covalent interaction between a protein and TLR4, exemplified by MD-2 binding the TLR4 ectodomain and contacting LPS.
What genes are involved in Toll-like receptor 4 binding?
Key genes include TLR4, LY96 (MD-2), MYD88, TICAM1, CD14 and IFI16, all of which participate in TLR4 recognition or downstream signaling [1,3,8].
Which protein binds TLR4 and LPS?
MD-2 (encoded by LY96) binds the TLR4 ectodomain and directly contacts LPS, forming the core recognition complex.
How is TLR4 binding inhibited?
TAK-242 (resatorvid) binds TLR4 selectively and interferes with interactions between TLR4 and its adaptor molecules.
Is TLR4 binding involved in thrombosis?
Yes, TLR4-dependent platelet-related thrombosis has been described in SARS-CoV-2 infection.
Is TLR4 binding relevant to Crohn's disease?
Platelet TLR4 has been studied in Crohn's disease, linking TLR4-dependent platelet activity to intestinal inflammation.
Can TLR4 binding be studied with CRISPR?
Yes, knockout, point-mutation, knock-in and overexpression models are used to test causality of TLR4-binding proteins [1,8].
What diseases are linked to TLR4 binding?
Infection-associated thrombosis, Crohn's disease and neuroinflammation are among the reported contexts [2,4,6].
How do I choose a model to study TLR4 binding?
Use knockout to test requirement, point mutation to dissect interface residues, knock-in for endogenous tagging and overexpression for gain-of-function studies [1,3,8].
Conclusion
GO:0035662 (Toll-like receptor 4 binding) captures the decisive molecular interaction that converts LPS detection into innate immune signaling. Structural, pharmacological and clinical studies converge on the TLR4-binding interface as both a mechanistic hub and a therapeutic target in infection, thrombosis, inflammatory bowel disease and neuroinflammation [1,2,3,4,6]. Because the function is defined by physical contact with TLR4, precise genetic models are essential for separating causal binding events from downstream correlations [1,8]. CRISPR-based knockout, point-mutation, knock-in and overexpression platforms, combined with library screening and bioinformatics, provide the experimental toolkit needed to interrogate this function in relevant cell types [2,7].
References
- 1. Matsunaga N et al.. 2011. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules.. Mol Pharmacol 79(1):34-41 PMID: 20881006
- 2. Carnevale R et al.. 2023. Toll-Like Receptor 4-Dependent Platelet-Related Thrombosis in SARS-CoV-2 Infection.. Circ Res 132(3):290-305 PMID: 36636919
- 3. Park BS et al.. 2009. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex.. Nature 458(7242):1191-5 PMID: 19252480
- 4. Schmid W et al.. 2017. Platelets Toll-like receptor-4 in Crohns disease.. Eur J Clin Invest 47(2):109-116 PMID: 27714784
- 5. Coutinho-Wolino KS et al.. 2022. Bioactive compounds modulating Toll-like 4 receptor (TLR4)-mediated inflammation: pathways involved and future perspectives.. Nutr Res 107:96-116 PMID: 36209684
- 6. Li J et al.. 2016. Therapeutic Developments Targeting Toll-like Receptor-4-Mediated Neuroinflammation.. ChemMedChem 11(2):154-65 PMID: 26136385
- 7. Verma S et al.. 2024. Toll-like receptor 4 pathway evolutionary trajectory and functional emergence.. Front Immunol 15:1494017 PMID: 39902049
- 8. Iannucci A et al.. 2020. Toll-like receptor 4-mediated inflammation triggered by extracellular IFI16 is enhanced by lipopolysaccharide binding.. PLoS Pathog 16(9):e1008811 PMID: 32903274
